Asset
CASDOZOKITUG
COHERUS ONCOLOGY INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06679985 | phase2 | active_not_recruiting | 2024-12-20 | 2027-09-01 | Coherus Oncology, Inc. | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma |
| NCT05359861 | phase2 | terminated | 2022-04-12 | 2025-06-30 | Coherus Oncology, Inc. | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma |
FDA applications (0)
This company has no applications containing this asset.